KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBIT (2016 - 2025)

Historic EBIT for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $115.6 million.

  • Sarepta Therapeutics' EBIT rose 1658744.65% to $115.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $298.8 million, marking a year-over-year increase of 68646.12%. This contributed to the annual value of $218.1 million for FY2024, which is 18142.7% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported EBIT of $115.6 million as of Q2 2025, which was up 1658744.65% from $161.7 million recorded in Q4 2024.
  • Sarepta Therapeutics' EBIT's 5-year high stood at $161.7 million during Q4 2024, with a 5-year trough of -$211.1 million in Q2 2022.
  • Over the past 5 years, Sarepta Therapeutics' median EBIT value was -$86.9 million (recorded in 2022), while the average stood at -$54.7 million.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 28120.32% in 2022, then soared by 1658744.65% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' EBIT stood at -$105.8 million in 2021, then fell by 0.96% to -$106.8 million in 2022, then skyrocketed by 123.05% to $24.6 million in 2023, then skyrocketed by 556.57% to $161.7 million in 2024, then dropped by 28.52% to $115.6 million in 2025.
  • Its EBIT stands at $115.6 million for Q2 2025, versus $161.7 million for Q4 2024 and $22.2 million for Q3 2024.